Gritstone bio (GRTS)
(Delayed Data from NSDQ)
$0.63 USD
0.00 (0.40%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.62 -0.01 (-1.23%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum F VGM
Brokerage Reports
Gritstone bio Inc. [GRTS]
Reports for Purchase
Showing records 1 - 20 ( 39 total )
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
Upcoming GRANITE Results Could Be a Major Catalyst; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
Our Learnings From Gritstone?s KOL Webinar on MSS-CRC; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
Focus Remains on GRANITE Phase 2 Study; Lower $4 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
Key GRANITE Readout Expected in March; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
Minor Delay to COVID Study; Focus on GRANITE Readout; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
Key Clinical Readout in 1Q24; COVID Phase 2 to Start; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
GRANITE Study On-Track; New Collaboration on ctDNA Monitoring; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
Prioritizing GRANITE Program With Readout in Early 2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
Key GRANITE Data Readout in 4Q23; Minimal Impact From SVB Closure; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
Collaboration With NCI to Test Cell Therapy Combo; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
Continued Progress in CORAL and SLATE; Adjust PT to $7; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
Positive CEPI Results Showcase CORAL?s Potential; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
Eyes on SLATE Update at ESMO; Promising CORAL Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
FDA ctDNA Guidance Bodes Well For Ongoing Studies; Lower PT to $12; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
SLATE Progress Expected in 2022; Adjusting PT to $15; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
Early CORAL Results Suggest Broad Immune Activity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Vaccine Results in Early Q1; SLATE Update Mid-2022; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
ESMO Update Provides Clarity on Path to Market; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S